Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions.
FoxP3+ regulatory T cells (Treg)
LCH cells
Langerhans cell histiocytosis (LCH)
T cells
active TGF-β
cytokines
mucosal associated invariant T cells (MAIT)
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
02
2022
accepted:
30
05
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Langerhans cell histiocytosis (LCH) lesions contain an inflammatory infiltrate of immune cells including myeloid-derived LCH cells. Cell-signaling proteins within the lesion environment suggest that LCH cells and T cells contribute majorly to the inflammation. Foxp3+ regulatory T cells (Tregs) are enriched in lesions and blood from patients with LCH and are likely involved in LCH pathogenesis. In contrast, mucosal associated invariant T (MAIT) cells are reduced in blood from these patients and the consequence of this is unknown. Serum/plasma levels of cytokines have been associated with LCH disease extent and may play a role in the recruitment of cells to lesions. We investigated whether plasma signaling factors differed between patients with active and non-active LCH. Cell-signaling factors (38 analytes total) were measured in patient plasma and cell populations from matched lesions and/or peripheral blood were enumerated. This study aimed at understanding whether plasma factors corresponded with LCH cells and/or LCH-associated T cell subsets in patients with LCH. We identified several associations between plasma factors and lesional/circulating immune cell populations, thus highlighting new factors as potentially important in LCH pathogenesis. This study highlights plasma cell-signaling factors that are associated with LCH cells, MAIT cells or Tregs in patients, thus they are potentially important in LCH pathogenesis. Further study into these associations is needed to determine whether these factors may become suitable prognostic indicators or therapeutic targets to benefit patients.
Identifiants
pubmed: 35844751
doi: 10.3389/fped.2022.872859
pmc: PMC9277082
doi:
Types de publication
Journal Article
Langues
eng
Pagination
872859Informations de copyright
Copyright © 2022 Mitchell, Kvedaraite, von Bahr Greenwood, Lourda, Henter, Berzins and Kannourakis.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2021 Apr 1;137(13):1777-1791
pubmed: 33075814
Sci Rep. 2018 Nov 7;8(1):16506
pubmed: 30405183
Clin Immunol. 2020 Jun;215:108418
pubmed: 32283322
Transl Res. 2018 Feb;192:15-29
pubmed: 29175264
J Immunol. 2005 Mar 1;174(5):3067-71
pubmed: 15728521
Br J Haematol. 2002 Apr;117(1):54-8
pubmed: 11918533
Radiographics. 2014 Nov-Dec;34(7):2008-24
pubmed: 25384298
Immunology. 2021 Dec;164(4):657-664
pubmed: 34240423
Blood. 2017 Jul 13;130(2):167-175
pubmed: 28512190
Acta Paediatr. 2021 Apr;110(4):1315-1321
pubmed: 32975844
J Pediatr Hematol Oncol. 2003 Jun;25(6):480-3
pubmed: 12794527
Sci Immunol. 2022 Apr;7(70):eabm9409
pubmed: 35363544
PLoS Med. 2007 Aug;4(8):e253
pubmed: 17696642
Pediatr Blood Cancer. 2006 Aug;47(2):194-9
pubmed: 16358318
Blood. 1999 Dec 15;94(12):4195-201
pubmed: 10590064
Blood. 2014 Sep 4;124(10):1655-8
pubmed: 24982505
J Interferon Cytokine Res. 2015 Oct;35(10):831-9
pubmed: 26381039
Cytokine. 2014 Dec;70(2):194-7
pubmed: 25086462
Br J Haematol. 2022 Jan;196(1):248-254
pubmed: 34435355
Blood. 2012 Dec 20;120(26):5199-208
pubmed: 23074278
Cytokine. 2017 Sep;97:73-79
pubmed: 28582647
Nat Med. 2021 May;27(5):851-861
pubmed: 33958797
Blood. 2017 Oct 26;130(17):1898-1902
pubmed: 28847997
Blood. 2016 Sep 1;128(9):1302-5
pubmed: 27365427
Cytokine. 2020 Feb;126:154877
pubmed: 31629106
Blood. 2021 Oct 7;138(14):1237-1248
pubmed: 34132762
Nat Med. 2008 Jan;14(1):81-7
pubmed: 18157139
Br J Cancer Suppl. 1994 Sep;23:S37-40
pubmed: 8075004
Blood. 2010 Sep 16;116(11):1919-23
pubmed: 20519626
J Leukoc Biol. 2019 Jan;105(1):101-111
pubmed: 30296338
PLoS One. 2014 Oct 24;9(10):e109586
pubmed: 25343480